Methylprednisolone inhibits the alternative and amplification pathways of complement.
Methylprednisolone sodium succinate limited the ability of zymosan or lipopolysaccharide to activate complement in normal serum by the alternative amplification pathways. Methylprednisolone limited B consumption in a reaction mixture which contained purified C3b, D, and B, indicating that soluble steroid directly inhibited the amplification pathway. The ability of soluble steroid to inhibit events in the alternative and amplification pathways of complement may provide a partial explanation for the effectiveness of steroids in treating gram negative septic shock.
D003167:Complement Activation / Q000187:drug effects*; D003179:Complement C3b / Q000378:metabolism*; D011415:Complement Factor B / Q000378:metabolism*; D011416:Complement Factor D / Q000378:metabolism; D003170:Complement Pathway, Alternative / Q000187:drug effects*; D004792:Enzyme Precursors / Q000378:metabolism*; D006801:Humans; D008070:Lipopolysaccharides / Q000494:pharmacology; D008775:Methylprednisolone / Q000031:analogs & derivatives*; D008776:Methylprednisolone Hemisuccinate / Q000494:pharmacology*; D015054:Zymosan / Q000494:pharmacology
D004792:Enzyme Precursors; D008070:Lipopolysaccharides; D008776:Methylprednisolone Hemisuccinate; D003179:Complement C3b; D015054:Zymosan; C493488:CFD protein, human; D011416:Complement Factor D; D011415:Complement Factor B; D008775:Methylprednisolone